Empagliflozin and Arterial Stiffness in Patients with Type 2 Diabetes: A Real-World Case-Control Study
In this clinical study, mid-term treatment with empagliflozin in patients with type 2 diabetes mellitus (T2DM) resulted in a significant reduction in arterial stiffness. Additionally, the improvement in the urine albumin-to-creatinine ratio suggests a potential enhancement in endothelial function. .
Authors
- F Tassone (ORCID: https://orcid.org/0000-0001-7583-1966)
- Mauro Feola (ORCID: https://orcid.org/0000-0002-8138-5189)
- Fabio Anastasio
- Guido Pastorini
- Giorgio Borretta
- Arianna Rossi
- Cinzia Ferreri
Institutions
- Ospedale Regina Margherita (IT)
- Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT)
- Ospedale Monaldi (IT)
- Ospedale Maggiore di Chieri (IT)
Publication Details
- Journal
- Endocrine Metabolic & Immune Disorders - Drug Targets
- Published
- 2025-02-18
- DOI
- https://doi.org/10.2174/0118715303372020250131060159
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29